Guidelines for imaging focal lesions in liver cirrhosis

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 5, 2008, Pages 697-703

  Lencioni, Riccardo ^a   Crocetti, Laura ^a   Della Pina, Maria Clotilde ^a   Cioni, Dania ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Computed tomography; Contrast enhanced ultrasound; Hepatocellular carcinoma; Liver cirrhosis; Magnetic resonance imaging

Indexed keywords

CANCER RISK; CONTRAST ENHANCEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DYSPLASIA; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; IMAGE ANALYSIS; KUPFFER CELL; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER NODULE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOVASCULARIZATION (PATHOLOGY); NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; RETICULOENDOTHELIAL SYSTEM; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; VASCULARIZATION;

CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; GUIDELINES AS TOPIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; TOMOGRAPHY, SPIRAL COMPUTED;

EID: 55349140031     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.5.697     Document Type: Review

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P, Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
3. Lencioni R, Cioni D, Della Pina C, Crocetti L, Bartolozzi C. Imaging diagnosis. Semin. Liver Dis. 25, 162-170 (2005).
4. Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C. Magnetic resonance imaging of liver tumors. J. Hepatol. 40, 162-171 (2004).
5. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 22, 983-993 (1995).
6. Tornillo L, Carafa V, Sauter G et al. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab. Invest. 82, 547-853 (2002).
7. Lencioni R, Caramella D, Bartolozzi C, Di Coscio G. Long-term follow-up study of adenomatous hyperplasia in liver cirrhosis. Ital. J. Gastroenterol. 26, 163-168 (1994).
8. Seki S, Sakaguchi H, Kitada T et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin. Cancer Res. 6, 3469-3473 (2000).
9. Borzio M, Fargion S, Borzio F et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J. Hepatol. 39, 208-214 (2003).
10. Roncalli M, Roz E, Coggi G et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 30, 1174-1178 (1999).
11. Park YN, Yang CP, Fernandez GJ, Cubukcu O, Thung SN, Theise ND. Neoangiogenesis and sinusoidal 'capillarization' in dysplastic nodules of the liver. Am. J. Surg. Pathol. 22, 656-662 (1998).
12. Ishak KG, Goodman ZD, Stocker JT. Tumors of the liver and intrahepatic bile ducts. In: Atlas of Tumor Pathology. 3rd series. Fascicle 31. Armed Forces Institute of Pathology, Washington, DC, USA (1999).
13. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005).
14. Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale in ultrasound. Eur. Radiol. 12, 151-165 (2002).
15. Quaia E, Calliada F, Bertolotto M et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 232, 420-430 (2004).
16. Albrecht T, Blomley M, Bolondi L et al. EFSUMB Study Group. Guidelines for the use of contrast agents in ultrasound. Ultraschall Med. 25, 249-256 (2004).
17. Nicolau C, Catala V, Vilana R et al. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur. Radiol. 14, 1092-1099 (2004).
18. Gaiani S, Celli N, Piscaglia F et al. Usefulness of contrast-enhanced perfusional Sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J. Hepatol. 41, 421-426 (2004).
19. Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 42, 27-34 (2005).
20. Kim CK, Lim JH, Park CK, Choi D, Lim HK, Lee WJ. Neoangiogenesis and sinusoidal capillarization in hepatocellular carcinoma: correlation between dynamic CT and density of tumor microvessels. Radiology 237, 529-534 (2005).
21. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 127, S133-S143 (2004).
22. Iannaccone R, Laghi A, Catalano C et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multi-detector row helical CT in patients with cirrhosis. Radiology 234, 460-467 (2005).
23. Tsai TJ, Chau GY, Lui WY et al. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127, 603-608 (2000).
24. Colli A, Fraquelli M, Casazza G et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and α-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 101, 513-523 (2006).
25. Rode A, Bancel B, Douek P et al. Small nodule detection in cirrhotic livers: evalnation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J. Comput. Assist. Tomogr. 25, 327-336 (2001).
26. De Ledinghen V, Laharie D, Lecesne R et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur. J. Gastroenterol. Hepatol. 14, 159-165 (2002).
27. Burrel M, Llovet JM, Ayuso C et al. Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38, 1034-1042 (2003).
28. Valls C, Cos M, Figueras J et al. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis value of dual-phase helical CT. AJR Am. J. Roenigenol. 182.
29. Ronzoni A, Artioli D, Scardina R et al. Role of MDCT in the diagnosis of hepatocellular carcinoma in patients with cirrhosis undergoing orthotopic liver transplantation. AJR Am. J. Roentgenol. 189, 792-798 (2007).
30. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-posuive interpretation. AJR Am. J. Roentgenol. 180, 1007-1014 (2003).
31. Freeny PC, Grossholz M, Kaakaji K, Schmiedl UP. Significance of hyperattenuating and contrast-enhancing hepatic nodules detected in the cirrhotic liver during arterial phase helical CT in pre-liver transplant patients: radiologic-histopathologic correlation of explanted livers. Abdom. Imaging 28, 333-346 (2003).
32. Kim T, Federle MP, Baron R et al. Discrimination of small hepatic hemangiomas from hypervascular malignant tumors smaller than 3 cm with three-phase helical CT. Radiology 219, 699-706 (2001).
33. Colagrande S, Centi N, Galdiero R, Ragozzino A. Transient hepatic intensity differences: part 2, those not associated with focal lesions. AJR Am. J. Roentgenol. 188, 160-166 (2007).
34. Ito K, Fujita T, Shimizu A et al. Multiarterial phase dynamic MRI of small early enhancing hepatic lesions in cirrhosis or chronic hepatitis: differentiating between hypervascular hepatocellular carcinomas and pseudolesions. AJR Am. J. Roentgenol. 183, 699-705 (2004).
35. Holland AE, Hecht EM, Hahn WY et al. Importance of small (< or = 20-mm). enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology 237, 938-944 (2005).
36. Krinsky GA, Lee VS, Theise ND et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Trampl. 8, 1156-1164 (2002).
37. Lauenstein TC, Salman K, Morreira R et al. Gadolinium-enhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am. J. Roentgenol. 189, 663-670 (2007).
38. Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur. Radiol. 17, 2519-2530 (2007).
39. Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin. Liver Dis. 19, 287-296 (1999).
40. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur. Radiol. 14, 559-578 (2004).
41. Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur. Radiol. 10, 1697-1702 (2000).
42. Grazioli L, Morana G, Caudana R et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest. Radiol. 35, 25-34 (2000).
43. Huppertz A, Haraida S, Kraus A et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 234, 468-478 (2005).
44. Scharitzer M, Schima W, Schober E et al. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J. Comput. Assist. Tomogr. 29, 181-190 (2005).
45. Youk JH, Lee JM, Kim CS. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am. J. Roentgenol. 183, 1049-1054 (2004).
46. Tanaka M, Nakashima O, Wada Y, Kage M, Kojiro M. Patomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 24, 807-812 (1996).
47. Lim JH, Choi D, Cho SK et al. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220, 669-676 (2001).
48. Kim SH, Choi D, Kim SH et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am. J. Roentgenol. 184, 1069-1076 (2005).
49. Kwak HS, Lee JM, Kim YK, Lee YH, Kim CS. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur. Radiol. 15, 140-147 (2005).
50. Kang BK, Lim JH, Kim SH et al. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 226, 79-85 (2003).
51. Pauleit D, Textor J, Bachmann R et al. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology 222, 73-80 (2002).
52. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47(1), 97-104 (2008).